TITLE:
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma

CONDITION:
Pancreatic Cancer

INTERVENTION:
G17DT Immunogen

SUMMARY:

      This study will test whether the G17DT Immunogen, when administered in combination with
      chemotherapy, is an effective and safe treatment for pancreatic cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Clinical diagnosis of pancreatic adenocarcinoma and unsuitable for pancreatic tumor
             resection

          -  Life expectancy of at least 3 months

          -  Functional status by Karnofsky Index of at least 70

        Exclusion criteria:

          -  Prior treatment with chemotherapy, radiotherapy, or anti-cancer immunotherapy

          -  Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or
             chronic obstructive pulmonary disease

          -  Immunodeficiency

          -  Bone marrow transplant within past year

          -  Brain metastasis
      
